modelArtesunate

Extends from Pharmacolibrary.Drugs.ATC.P.P01BE03.

Information

name:Artesunate
ATC code:P01BE03
route:intravenous
compartments:2
dosage:120mg
volume of distribution:0.17L
clearance:2.8L/h/kg
other parameters in model implementation

Artesunate is a semi-synthetic derivative of artemisinin, used for the treatment of severe and uncomplicated malaria. It acts rapidly against Plasmodium species and is recommended by WHO as first-line therapy for severe malaria. Artesunate is not approved in the US or EU for oral use but is used intravenously in many countries.

Pharmacokinetics

Pharmacokinetic parameters reported for adult patients with severe malaria treated with intravenous artesunate.

References

  1. Zaloumis, SG, et al., & Simpson, JA (2014). Population pharmacokinetics of intravenous artesunate: a pooled analysis of individual data from patients with severe malaria. CPT: pharmacometrics & systems pharmacology 3(11) e145–None. DOI:10.1038/psp.2014.43 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25372510

  2. Cen, YY, et al., & Zhou, H (2018). [Research progress on pharmacokinetics and pharmacological activities of artesunate]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 43(19) 3970–3978. DOI:10.19540/j.cnki.cjcmm.20180726.010 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30453725

  3. Haghiri, A, et al., & Simpson, JA (2023). Evidence Based Optimal Dosing of Intravenous Artesunate in Children with Severe Falciparum Malaria. Clinical pharmacology and therapeutics 114(6) 1304–1312. DOI:10.1002/cpt.3041 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37666798

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)